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Abstract  The purpose of this article is to high-
light a number of underlying issues that may be 
useful for a comprehensive review of the manage-
ment of Health-Related Science, Technology and 
Innovation policies (ST&I/H), and its strategies 
and priorities. It is an analytical study supported 
by an extensive review of the technical and jour-
nalistic literature, clippings, legislation and feder-
al government directives. The results show that the 
Healthcare Production Complex undeniably and 
increasingly needs science to maintain itself. One 
may infer that a framework of institutional mile-
stones is being built in Brazil, to strengthen, guide 
and encourage Research and Development, and 
that clinical research creates scientific knowledge 
to address public healthcare issues by generating 
new inputs or enhancing existing techniques, 
processes and technologies that will be produced, 
marketed and used in the different segments, thus 
feeding the Healthcare Productive Complex.
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Introduction
This study addresses the structure of the SNIS 
(NHIS) - the National Healthcare Innovation Sys-
tem - as the interface with SUS, the Unified Health-
care System, as this connection is an important so-
cial and economic element for the country. 
To understand clinical studies as a window of 
opportunity to foster innovation, one must first 
introduce the historical context in which the De-
partment of Science and Technology (Decit) was 
created within the Ministry of Health. A number 
of concepts were defined wit this in mind, and 
also considering that this structure, as the formal 
structure to promote different relevant activities 
- research, knowledge dissemination, and product 
and process development -, interacts and creates 
links that provide specific knowledge and compe-
tence, in search of an effectively innovative per-
formance1. 
We designed a framework that promotes the 
sustainability of Science, Technology and Inno-
vation (ST&I) and regulation in Brazil, along 
with the public policies to strengthen it. It also 
fosters windows of opportunity crated from net-
work arrangements provided by clinical research 
- one of the strategies to produce healthcare 
goods and services. 
Its purpose is to highlight a number of un-
derlying issues that may be useful for a compre-
hensive review the theme to manage health-relat-
ed Science, Technology and Innovation policies 
(ST&I/H), and its strategies and priorities.
Regarding the approach to network possibili-
ties, links and collaborations, we reveal the main 
players in creating measures that support pro-
cesses. We also present potential arrangements 
of the players in the National Network of Clin-
ical Research, showing the elements to consider 
when designing partnerships that will foster and 
strengthen ST&I/H in Brazil. 
This is an analytical paper supported on an 
extensive review of domestic and international 
literature related to the tools and policies used to 
strengthen science, technology and innovation in 
health in Brazil. We performed non-systematic 
searches for articles and dissertations in the main 
scientific databases, in addition to the so-called 
“grey literature”. Other sources of data included 
book chapters, technical and journalistic texts, 
legislation and federal government directives. 
This article is a segment of the Ph.D. dissertation 
of the main author, entitled “Managing networks 
for scientific, technological and innovation in 
healthcare in Brazil”. 
National System for Innovation 
in Healthcare
In the late 1980s the concept of a National In-
novation System (NIS) first emerged in studies by 
Freeman2, to explain the economic performance 
of Japan at that time. This a set of diverse insti-
tutions focused on generating, incorporating, 
using and disclosing knowledge sourced from 
companies, organizations and other institutions 
involved in the process2. This is also explored to 
explain how knowledge and innovation deter-
mine national competitiveness, especially as this 
new concept extrapolates the individual focus 
when associated with organizational analysis. The 
studies of Freeman2, Lundvall3, and Nelson4, in 
Costa5 are considered the origin of this concept.
The process leading up to the National Health 
Innovation System in Brazil included in particu-
lar the development of a theoretical framework 
from which derives the concept for the Econom-
ic-Industrial Healthcare Complex6,7.  This in 
turn is based on a social-development project, 
enabling articulation between social inclusion, 
mass consumption, increased jobs and income, a 
stronger manufacturing structure, and innovative 
processes and investments, potentially reducing 
nation’s dependence, which according to Costa5:  
...the political-institutional framework of the 
Economic-Industrial Healthcare Complex is influ-
enced by the activity of the State (relationships of 
power, decision-making structures and formula-
tion of implicit and explicit policies), institutions 
(from formal education and S&T institutions, to 
development and funding agencies, for example all 
the way to standards of conduct embedded in so-
ciety), an organized civil society (associations for 
example), and the population in general.
It is clear that innovation in healthcare in-
volves a field of excellence, given that it is able to 
mobilize the ST&I/H infrastructure and articulate 
with the industrial base to promote its consoli-
dation. Furthermore, it is seen as a political and 
social process, as it is part of the nation’s strategic 
planning, focused on reducing the its dependence 
on health-related inputs manufactured abroad, 
reinforcing the nation’s economic policy8,9. 
Policies and actions: development 
of the regulatory framework 
and Science and Technology incentives
Among the instruments and policies designed 
to support ST&I/H measures, one should high-
light the National Policy for Science, Technology 
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and Innovation in Health, and its articulation 
with the National Healthcare Policy and the Na-
tional Science, Technology and Innovation Pol-
icy. We understand that their guiding principles 
and strategies are tools to facilitate the interface 
between the State, the market and the scientific 
community on behalf of the Unified Healthcare 
System (SUS)10,11. 
The National Agenda of Healthcare Research 
Priorities (ANPPS) includes one of the Nation-
al Policy for SC&I strategies, and takes on the 
important role of guiding measures to foster re-
search and training of human resources for the 
SUS, enabling efforts on behalf of areas that are 
actually a part of the strategic elements that ad-
dress public healthcare problems at the local and 
national level.
The development of the National Agenda 
of Healthcare Research Priorities had the ample 
support of the scientific community, healthcare 
managers and social control representatives in 
Health, Education, Science & Technology and 
Social Services. A number of city, state, regional 
and national seminars were held as part of this 
process, culminating in the 2nd National Confer-
ence on Science, Technology and Innovation in 
Healthcare (CNCTIS) in 200412-14.   
The National Conference on ST&I/H became 
a political-democratic tool, considering the fol-
lowing elements of how and why it was created: i) 
the healthcare situation and life conditions of the 
Brazilian population - systematized in the publi-
cation entitled Saúde no Brasil: Contribuições para 
a Agenda de Prioridades de Pesquisa (Healthcare 
in Brazil: contributions to the Agenda of Research 
Priorities); ii) the definition of sub-agendas in 
research, created by a Technical Advisory Com-
mittee made up of experts and managers; iii) the 
definition of research themes listed by working 
groups for discussion in each sub-agenda10,13. 
Thus, the National Agenda of Healthcare 
Research Priorities and the National Policy for 
ST&I/H are the guiding instruments for ST&I/H 
measures within the Ministry of Health Depart-
ment of Science, Technology and Strategic Inputs 
(SCTIE).
Another initiative that has contributed to 
positive changes in S&T in Brazil was the cre-
ation of Sector Funds in 1999, under the manage-
ment of FINEP, the agency that funds studies and 
projects, part of the Ministry of Science, Tech-
nology and Innovation. This venture picked up 
pace when a set of tools, policies, programs and 
laws favorable to the National Innovation System 
came into effect15. 
Chart 1 is a chronology of the main tools 
and policies that contributed to a more robust 
ST&I/H, and are strong allies in fostering inno-
vation in healthcare.
The instruments in the chronology are not 
exhaustive. Numerous other instruments, for 
example terms of cooperation signed by the 
MoH and MST&I have enabled and facilitated 
the implementation of a set of measures that fa-
vor, strengthen and collaborate to intensify the 
demand for R&D/H and ST&I/H, promoting 
greater reliability for the players involved in gen-
erating products and processes - universities, re-
search centers and public and state-owned com-
panies -, along with investors and consumers16.
This analysis shows that a framework of in-
stitutional milestones is being created in Bra-
zil to strengthen, guide and incentivize R&D/H 
and ST&I/H activities in the country, and also to 
articulate with the incentives of the productive 
sector. However, it is also important to point out 
the increment in S&T provided by the CNPq, the 
National Council for Scientific and Technologi-
cal Development starting in the 1950s, by Fapesp, 
the state of São Paulo Foundation for Research 
Support created in 1962, and by Finep, which 
since 1971 has funded studies and projects17. 
Real articulation between the players across 
these policies may facilitate access to results, at-
tract foreign S&T for innovation in Brazil, and 
provide the State with tools to respond to in-
creasing social and market pressure to incorpo-
rate high-value added, high-technology products 
into SUS16. 
Department of Science and Technology 
and Research Promotion
At the federal level, responsibility for foster-
ing, monitoring and assessing health research 
projects are the prerogative of the Department 
of Science and Technology, part of the Depart-
ment of Science, Technology and Strategic In-
puts (SCTIE) of the MoH. This is the main agent 
in charge of enforcing the National Policy for 
ST&I/H, promoting inter-sector articulation of 
the National System for Science and Technology 
in Healthcare. 
Following the 2nd National Conference on 
ST&I/H, which approved the PNCTIS and Na-
tional Agenda of Healthcare Research Priorities, 
the Department of Science and Technology be-
came the main player in fostering R&D in the 
area of health in Brazil, incorporating an import-
ant differential compared to the previous model 
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Chart 1. Breakdown of the main political tools related to scientific development, research, training in science 
and technology and innovation. Listed in chronological order.
Year Instrument Comment
1990
Law 8,080/1990 
(Art. 15 § XIX) 
Defines that it is the responsibility of SUS to foster research and studies in health-
related areas. 
1994
1st CNCTIS 1st National Conference on Science, Technology and Innovation in Health - 
promoted the institutionalization of the political debate of SUS responsibilities in 
fostering R&D/H. 
1999
Sector Funds Funding for research, development and innovation projects. The Healthcare area 
is responsible for: CT-Health, CT-Infrastructure, CT-Biotechnology, CT-Green/
Yellow, and for all cross-sectional activities involving more than one fund.
2001
Millennium 
Institute Programs
Stimulates the development of inter-laboratory research networks to capture all of 
the potential of the existing physical infrastructure.
2004
2nd CNCTIS 2nd National Conference on Science, Technology and Innovation in Health 
- brought together the goals of the National Healthcare Policy and those of the 
National Policy for Science and Technology, increasing the interaction between 
Health, Education, Science and Technology.
PNCTIS National Policy for Science, Technology and Innovation in Health - defines that 
national development in ST&I/H proceed sustainably, supported on the production 
of technical and scientific knowledge adjusted to the economic, social, cultural and 
political needs of the country.
ANPPS The National Agenda of Healthcare Research Priorities guides the research priorities 
to be promoted, according to the principles of the unified system (SUS).
Law 10,973/20204 
- Innovation Law
Defines measures to incentivize ST&I within the productive environment for 
developing capabilities and enabling the country to achieve technological and 
industrial development autonomy. 
PITCE The National Policy for Industry, Technology and Foreign Trade defines innovation 
as a core dimension of the manufacturing and foreign trade policy.  
Law 11,105/2004 
Biosafety Law 
Sets safety guidelines and defines mechanisms to oversee activities involving 
Genetically Modified Organisms (GMO) and their derivatives.
2005
Law 11,196/2005 
“Lei do Bem” (Law 
of the Good)
Provides tax incentives for technological innovation.
2006
Economic 
Subvention 
Program
Fosters innovation and increased competition among the nation’s companies and 
its economy.
2007
PACTI 
(2007- 2010)
Action Plan for Science, Technology and Innovation, sought to increase scientific 
and technological production in the country.  
2008
PDP Production Development Policy - improves the various sectors of Economic 
Industrial Complex, including partnerships between businesses and universities.
GM/MS Directive 
1,942/2008 
GECIS
Created the Industrial Healthcare Complex Executive Group to implement the 
Brazilian framework governing strategies to strengthen the CEIS, the Production 
and Innovation in Healthcare Complex.
INCT Program Program of the National Institutes for Science and Technology. 82 INCT in health-
related areas, out of 252 incentivized in 2016.
GM/MS Directive 
978/2008
Selects the projects that are strategic for SUS. Prioritizes promotion of RD&I and 
the manufacture of vaccines, blood derivatives and products for neglected diseases.
2009
PNGTS The National Policy for Technology Management in Healthcare promotes 
management activities related to the assessment, incorporation, disclosure, 
management, use and withdrawal of technologies within the healthcare system.
Law 12,101/2009
Proadi - SUS 
Created the Program to Support the Institutional Development of SUS (Proadi 
- SUS), supporting research strategic for SUS with tax exemption funds. This 
includes the Hospitals of Excellence program.
it continues
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used by development agencies, in that it involved 
representatives of the scientific community and 
market segments, as well as healthcare managers, 
in the definition of the lines of research to be pro-
moted18,19.
In 2004, the ceremony for the 2nd CNCTIS, 
made up of state conferences held in all states 
except Roraima, Tocantins and Goiás, and 307 
regional and city conferences, had 15 thousand 
participants, including delegates, guests and ob-
servers. In addition to approving the National 
Policy for ST&I/H and the National Agenda of 
Healthcare Research Priorities, discussions in-
cluded the need to reflect on the tools available 
at the time to make the new National Policy for 
ST&I/H management model operational. The 
aim was to create a development agency for this 
purpose12,20. 
Considering this, under the theme “Why have 
a development agency linked to the Ministry of 
Health?” professor Reinaldo Guimarães, then the 
director of Decit, presented a panel that defend-
ed the creation of a development agency to effec-
tively help implement and enforce the National 
Policy for ST&I/H and the National Agenda of 
Healthcare Research Priorities, ensuring more 
effective processes. However, there was no con-
sensus to approve the creation of such an agency.
DECIT, the Department of Science and Tech-
nology, was created within the Executive De-
partment of the Ministry of Health in 2000, and 
became part of the Department of Science, Tech-
nology and Strategic Inputs when it was created 
in 2003. In its current structure (Figure 1), it has 
61 professionals specialized in the finalistic area 
of coordination to which it belongs. 30% of these 
have PhDs, 26% have Master’s Degrees, 31% are 
Specialists and the others have undergraduate 
degrees in some health or related area. 
Within the Department of Science and Tech-
nology, promotion became effective and grew 
thanks to the cooperation agreements signed by 
the Ministry of Health and the Ministry of Sci-
ence, Technology and Innovation. This enabled 
Year Instrument Comment
2010
Law 12,349;2010 
- Government 
Purchases Law
Promotes the replacement of imported manufactured goods and services with 
domestic ones resulting from technological innovation and development performed 
in Brazil. 
2010
National Graduate 
Studies Plan 
(2011-2020)
Prioritizes R&D in health-related areas, promotes research combining graduate 
studies, businesses and society, stimulates university-business partnerships, 
promotes international cooperation, contributes to strengthening the National 
Institutes of Science and Technology and the Research, Dissemination and 
Innovation Centers; promotes a stronger National Network of Clinical Research.
2011
PESS Agenda The agenda for Research Strategic to the healthcare System defines the SUS lines of 
research to meet the strategic goals of the 2012- 2015 Multi-Year Plan.
The 2011-2014 
Greater Brazil 
Program
Strengthened the manufacturing, innovation and national competitive chains, 
following the PDP and PITCE lines of action to support, develop and implement 
business technology portfolios. 
Law 12,401/2012 Created Conitec, the SUS National Committee to Incorporate Technologies. This 
committed advises the MoH in the incorporation, exclusion or changes in new 
healthcare technologies within SUS.
2012
National CTI 
Strategy for 2012-
2015
Enhanced business innovation and consolidated the National Innovation System. 
GM/MS Directive 
n°. 4/10
Defined guidelines and criteria for production development partnerships; fostered 
partnerships between public and private institutions, encouraging technology 
transfer to Brazil.
CNS Resolution 
466/2012  
Governs guidelines and standards of research involving human beings.
Law 12,715/2012
Pronon and 
Pronas/ PCD
Created the National Program to Support Oncological Care (Pronon) and the 
National Program to Support Healthcare for People with Special Needs (Pronas/
PCD), which encourages actions and services developed by private, non-profit 
entities, associations and foundations in the areas of oncology and people with 
special needs, using funds coming from Income Tax deductions.
Chart 1. continuation
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the transfer of funds from the National Health-
care Fund to the National Fund for the Develop-
ment of Science and Technology, thus allowing 
its development agencies - CNPq and Finep, to 
perform all of the procedures require to contract 
projects under Decit. 
This partnership is often referred to as the 
“perfect marriage”, as the funds invested and 
projects contracted over the years (2004-2015) 
would not have been possible without the exper-
tise of these agencies. Decit promotes projects in 
three ways:
	 National Promotion: public calls that 
involve free competition for theme-based re-
search projects, open to any institution in the 
country. 
	 Decentralized Promotion: multi-
ple-theme based public calls promoted by states, 
and open only to local institutions. This includes 
the SUS Research Program (PPSUS), which calls 
for projects based on local needs and research 
themes listed by the local scientific community 
and the State Department of Health. Program 
management is shared between CNPq and the 
Research Support Foundations (FAP) in each 
state. The SUS Research Program has strong ap-
peal among the scientific community, as it helps 
reduce S&T inequality, historically an issue across 
the different regions in this country;
	 Direct Contracting: this is used in re-
sponse to emergency or specific public health de-
mands, such as the recent contracting of studies 
to fight the problems caused by the Zika virus. 
The Department of Science and Technology 
contracts research either through contracts and 
agreements, or by decentralizing resources to 
Year Instrument Comment
2013
INOVA-SAÚDE 
(2013-2017)
This program supports RD&I in public and private institutions working within 
CEIS, enabling continued funding of projects with the potential of reducing the 
nation’s technological dependence in inputs used for healthcare. 
GM/MS Directive 
n°. 3,089
Prioritizes scientific and technological development of biomaterials and items 
related to oncology, non-transmissible chronic diseases, neglected diseases, viral 
diseases, STDs and AIDS.
Decree 8.065/2013
§ 31
Stipulates that the Department of Science and Technology (Decit) will be involved 
in formulating, implementing and assessing PNCTIS, based on the requirements 
of the PNS and within the SUS principles and guidelines; coordinate and execute 
MoH activities in health-related R&D and promote inter-sector articulation within 
the National System of Science and Technology.
GM/MS Directive 
n°. 2,531/2013
Redefines the list of priority items for SUS investments in R&D and manufacture, 
and creates the PDP. 
PNPC National Knowledge Platform Program, supports partnerships between businesses 
and science and technology research institutions in Brazil and abroad for on-
demand technology and innovative products, processes or services involving a 
technological risk. 
2015 CNS Resolution 
nº. 506/ 2016
Regulates the accreditation of Research Ethics Committees (REC), which make up 
the REC/CONEP System and provides other guidelines. 
Constitutional 
Amendment 
nº. 85/2015 
National S&T Code - amends and adds provisions to the Federal Constitution to 
update how the activities of Science, Technology and Innovation are handled.
2016 Law 13,243;2016 SC&I Legal Framework governing stimulus to scientific development, research, and 
the development of capabilities in science, technology and innovation.
Fonte: Prepared by the authors based on Iozzi21, Botelho and Alves 9, Almeida-Andrade16, Vargas et al.22.
Chart 1. continuation
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administrative partners. Agreements are operat-
ed by the government agreement management 
system (Gescon and Sincov), and the National 
Health Fund, or by decentralizing funds in the 
case of partnerships with MCTI agencies (CNPq 
and Finep) and Capes (Coordination for the Im-
provement of University Level Personnel), part of 
the Ministry of Education, or the state-level Re-
search Support Foundations, by releasing funds 
to the CNPq, which manages the agreements. 
Over the past five years (2011-2015), Decit 
invested some R$ 509 million in 1,615 research 
projects, 97% of which were the result of public 
calls for projects. This investment enabled the ex-
pansion and consolidation of the following initia-
tives: The National network of Clinical Research 
(RNPC), the Brazilian ATS Network (Rebrats), 
the National Network for Cell Therapy (RNTC), 
the National Network of Research in Neglected 
Diseases (RNPDN), the National Network for 
Research into Healthcare Policies (RNPPS), the 
National Network of Research into Cerebral Vas-
cular Diseases (RNPAVC), the National Network 
of Clinical Research in Cancer (RNPCC), and the 
National Network for Research in Cardiovascu-
lar Diseases (RNPDC). It also fostered technical 
cooperation at the national and international 
level, and the strengthening of ethics and valua-
tion of the National Research Ethics Committee 
(Conep), and the Research Ethics Committees 
(RECs). 
Investments in Research and Development
The legacy of Joseph Schumpeter23 is a pri-
mary reference for addressing relationships that 
involve innovation and economic development. 
According to the author, economic growth is a 
dynamic process and is, above all, a “process of 
creative destruction”, essentially depending on 
the generation and use of innovations associat-
ed with the processes involved in their dissemi-
Figure 1. Organization Chart for the Department of Science and Technology (Decit).
Source: The Authors based on documents provided by Decit. 
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nation, such as exploring new markets and new 
business dynamics5,23,24.
In short, one gleans from this that RD&I/H 
creates opportunities for investment, employ-
ment and income, thus creating an active space 
of economic development, which according to 
Viana et al.25, emerges from adaptations across 
sub-systems at different moments in time, 
strengthened by a specific link to the manufac-
ture of medical inputs, equipment, materials and 
drugs, that today is the main dimension used to 
define the direction of healthcare policies all over 
the world. 
Historically, the government has been the 
main source of funding for R&D in Brazil16,24,26. 
In developed nations however, private invest-
ment in this area grows faster than government 
investments, which range from about 2 to 4% 
of the GDP, as shown in Graph 1. Brazilian gov-
ernment investment has remained pretty much 
stable since 2008, while private sector investment 
increased somewhat27. Regarding private invest-
ment, among BRIC nations Brazil is behind Chi-
na, which gets more of this type of incentive.
According to the Unesco Science Report enti-
tled Towards 2030:
With its strong demand for commodities to 
feed a fast-growing population, China has pro-
tected exporting nations from falling demand in 
North America and the EU, since 2008. However, 
the most recent analysis reveals that the commod-
ity boom has reached an end, revealing structural 
deficiencies, in particular in Brazil and the Russian 
Federation27.
Expenses with drugs and the like are quite 
significant in Brazil. Table 1 compares total 
spending with drugs and Ministry of Health 
R&D investment in Pharmaceutical Care com-
pared to the percent total MoH budget over the 
course of five years.
Promoting ST&I in drugs, medicines and 
healthcare inputs is believed to be aligned with 
policies and instruments created to strengthen 
the area. This premise is supported by Vargas et 
al.28, when they talk about the involvement of 
different players on behalf of a recovery of the 
Brazilian production base:
[...] it involves increasing articulation between 
manufacturing, technology policies and the health-
care area, as well as a return of growth policies, re-
flecting in the recognition of a strong interface be-
tween healthcare and the new biotechnology, nano-
Governmental investment (%)
Graph 1. Government and private investment in R&D as a percent of GDP in different countries.
Source: Ministry of Science, Technology and Innovatoin (2015), Apud Unesco (2015), suitably adapted.
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technology and advanced specialty chemicals-relat-
ed technological platforms, and their importance to 
the nation’s manufacturing basis [...].
In this sense, one of the strategic areas to 
foster innovation resulting in new drugs for the 
population is Clinical Research, which acts as 
a bridge between biotechnology research and 
manufacturing. This converges with the debate 
that includes S&T production for generating 
inputs to face health issues. In other words, an 
interface between production & innovation and 
care is created. The State, as the intermediary, 
formulates and enforces measures to generate 
development for the social apparatus29. 
Unlike other market goods such as electron-
ics or food, health is a public asset, also subject to 
market failures, but one that involves human life, 
the greatest asset of all30. 
This premise justifies the State’s commitment 
to not give up its regulator role, providing con-
trol and vigilance mechanisms that can ensure 
the safety of healthcare products (drugs, med-
icines and other inputs), even if the State itself 
promotes their manufacture30. Supporting the 
healthcare process requires involving numerous 
different players in a range of networks, built 
specifically for this context, but without ignoring 
individual safety and care.
Contributing to this context, Vianna et al.30 
said:
Over time, both productive and social moti-
vations for healthcare were built on discussions 
involving RD&I on the one hand, and ethics, and 
the right to and ensured access to quality health-
care services on the other. Over time, understand-
ing how these interests are interrelated was decisive 
for designing policies and integration mechanisms.
Specificities of clinical research
The priorities of clinical research should be 
included in all 24 sub-agendas of the National 
Agenda of Healthcare Research Priorities as a 
strategy.
Niches with a high potential for success are 
vaccine and immunobiological production, and 
new diagnostic techniques. New products for 
treatment, prevention and health promotion 
such as herbal medicines, drugs and medicines, 
blood derivatives, homeopathic drugs and inputs 
for supplemental practices, as well as health pre-
vention and promotion11,28. 
Even though National Agenda of Healthcare 
Research Priorities is unquestionably relevant 
for equal distribution of research funds, it is also 
essential to consider that, while desirable, pro-
fessionals are not always ready to use the results. 
Bringing together those who do research and 
those who make policies could be a strategy to 
consider31,32. 
Clinical research as performed at universities 
and teaching and research institutions contrib-
utes to this premise, as it provides opportunities 
for training healthcare professionals, technical 
and scientific exchange, development and im-
provement of teaching and research methods, 
and new therapeutic options for patients, which 
can be used by hospital managers to help steer 
teaching, research and care activities. 
According to the National Institutes of Health 
(NIH)33:
Clinical Research is research on human beings 
(or on materials of human origin such as tissues, 
specimens or cognitive phenomena), where an in-
vestigator (or team member) interacts directly with 
participants. In-vitro studies using human tissue 
not associated with a living individual are exclud-
ed. Clinical research includes: (a) the mechanisms 
of human disease; (b) therapeutic interventions; 
(c) clinical trials; (d) the development of new tech-
nologies. 
Clinical research is also used by healthcare 
managers to make decisions, with studies to 
supplement scientific evidence and subsidize 
decisions common to the practice of Healthcare 
Technology Assessment. This practice is based on 
the premise of defining clinical guidelines and 
protocols, regulating drug prices and formal pol-
icies for assessment, incorporation and manage-
ment of technologies within SUS34. 
Clinical trials are one type of clinical research, 
designed to investigate the efficacy and safety of 
medicinal products and medical procedures in 
human beings, making it possible for them to be 
used in medical practice. For the most part they 
are multi-center, multi-institutional and some-
times multi-sector or multi-national, depending 
on the complexity involved in the processes in 
question. 
They tend to involve centers of excellence 
with highly trained professionals using research 
protocols designed according to strict ethical and 
good clinical practice criteria, solid knowledge 
bases and backed by prior studies and knowledge 
of how the target disease evolves. 
The entire clinical process, from planning 
through study end, must follow well established 
regulations set by the agencies created to protect 
participant rights (Conep and Anvisa in Brazil), 
ensuring results of high scientific quality35,36. 
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These studies are conducted in phases, as shown 
in Figure 2. If the results of a phase are positive, 
the study moves on to the next one. 
Each phase in clinical trials must complete 
certain elements in order to achieve scientifically 
robust and reliable results. This is general data as, 
in the case of clinical trials for some pathologies, 
such as in the complex case of cancer, certain 
specificities must be taken into consideration.
It is estimated that market introduction of a 
new drug/medicine requires some ten years of 
R&D and ~US$ 1 billion in research. This leads 
to multi-sector agreements involving the govern-
ment, development agencies, universities, hospi-
tals, etc. for creating public-private partnerships 
(PPPs)30. 
Final Considerations 
The discussion presented herein includes numer-
ous theoretical milestones created over the years, 
all of which contribute to understanding and list-
ing the elements that have been strengthened in 
S&I/H and RD&I/H, and how one can take ad-
vantage of the windows of opportunity that open 
up, given the direction inherent to each one. 
Regarding the milestones we analyzed, the 
federal government has clearly made an effort 
to provide the instruments required to promote 
Table 1. Ministry of Health budget and spending on drugs over time.
Actions 2011 2012 2013 2014 2015
Strategic medicines 162.000.000 124.000.000 134.834.524 164.730.448 340.000.000
Basic medicines 1.060.000.000 1.077.448.725 1.213.500.000 1.292.642.028 1.230.000.000
Exceptional medicines 3.521.496.999 4.082.150.000 4.977.534.000 4.890.845.854 5.867.474.795
AIDS Medicines 804.802.000 823.600.000 770.200.000 864.187.200 1.101.000.000
Immuno-biologicals 1.613.204.809 1.676.500.000 2.181.900.000 2.296.719.000 3.300.672.000
Coagulopathy medicines 412.565.000 552.300.000 747.915.000 583.432.574 802.500.000
Budget drugstores 774.605.000 1.410.000.000 1.856.600.000 2.460.838.514 3.261.328.000
SUB-TOTAL – MEDICINES 8.348.673.808 9.745.998.725 11.882.483.524 12.553.395.618 15.902.974.795
Innovation and Production 56.860.300 64.900.000 72.720.000 55.525.381 50.160.000
Modernization of the 
Manufacturing Park
0 130.000.000 160.000.000 106.400.000 46.800.000
Laboratories Official 0 70.000.000 0 0 0
Research 77.337.653 81.392.000 93.685.000 90.305.000 84.128.000
Structing – A.F. 10.972.576 25.000.000 39.000.000 69.399.580 84.152.000
GRAND TOTAL 8.493.844.337 10.117.290.725 12.247.888.524 12.875.025.579 265.240.000
MoH Budget 63.113.634.859 78.361.160.095 84.051.839.071 108.393.354.888 121.154.205.789
% 13% 12% 14% 12% 13%
Source: Department of Science, Technology and Strategic Inputs/MoH.
the production of health and healthcare. One in-
teresting question is the possibility of a conflict 
of interest between private enterprise and public 
healthcare (market vs. State). 
It is essential to understand what science, 
technology and innovation mean within the 
dynamics of the different players. For example, 
including the pharmaceutical industry in part-
nerships for performing clinical trials, using the 
infrastructure created within the RNPC, may be 
a strategy to strengthen the necessary develop-
ment of clinical research in Brazil.
In this scientific scenario surrounding clinical 
research, the key player is the investigator-entre-
preneur, who mobilizes members of the scientific 
community to identify shared expertise to create 
a network of collaboration, partnering with the 
government and private sector to create a “shared 
management structure”. 
This teaches us that collaboration as a net-
work, as described by Martins38, enables the in-
corporation and sharing of knowledge in produc-
tion processes. Added to this is the fact that, when 
signing a partnership agreement and sharing re-
sources, each player enables strategic directional-
ity, in the sense of composing the mission, goals 
and functions of this type of bond, expressed in 
the agenda of priorities defined by SUS.
The Healthcare Production Complex unde-
niably and increasingly needs science to maintain 
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itself. Clinical research creates scientific knowl-
edge to tackle public health issues, using sub-
sidies to generate new technologies or improve 
existing techniques, processes and technologies, 
produced, marketed and sold in the different seg-
ments, and thus feeding the entire Economic-In-
dustrial Healthcare Complex.
This movement culminates in the under-
standing of Dal Poz39 and the support of Latour’s 
Actor-Network Theory40, which in addressing the 
limits of a network, warns us not to limit them to 
the number of players, but use the environment 
defined by the flow of artifacts that circulate and 
Figure 2. Phases of the Research and Development Process.
 
Source: Pinho et al.37.
enable sharing resources, including financial re-
sources. This environment is nothing more than 
the National Innovation System, with its set of 
S&T policies and technology and regulatory re-
gimes. This idea covers networks and their con-
nections. 
Thus, assessing these relationships in the 
context of this article means considering the pro-
gressive strengthening and extension of the in-
teraction between the research and development 
system and the healthcare production system, 
and its ability to fund itself, and management of 
the State regulatory structure.
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Molecular Research
Proof of Concept
Laboratory and animal safety 
and efficacy studies
Phase I Phase II Phase III Phase IV
Basic Research Pre-Clinical Trials
Clinical Tests Pharmacovigilance
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